Metastatic Prostate Cancer Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metastatic Prostate Cancer Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Metastatic Prostate Cancer Market by downloading the comprehensive report from DelveInsight @ Metastatic Prostate Cancer Therapeutics Market
Key Takeaways from the Metastatic Prostate Cancer Market Report
In September 2024:- Bayer- The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC).
The Metastatic Prostate Cancer Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
Based on DelveInsight’s assessment in 2023, the 7MM had approximately 240,300 prevalent cases of metastatic prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024−2034).
Around 45% of all metastatic prostate cancer cases are attributed for mCSPC and ~55% accounted for mCRPC.
As per the estimates, in the US, majority of the cases were found to be localized/ locally advanced cases (Stage I-III), comprising approximately 60% of total cases, while nearly 32% belonged to biochemical recurrence/ progressive cases, and ~8% belonged to metastatic cases.
Prostate cancer is most frequently diagnosed among men aged 65–74 years. Analysis indicates that age-specific data differs across various geographic regions. In the US, prostate cancer was least prevalent among individuals aged over 84 years, whereas in Japan, the lowest number of cases were observed in the age group of 54 years or younger.
The leading Metastatic Prostate Cancer Companies such as AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
Promising Metastatic Prostate Cancer Therapies such as ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.
Gain a competitive edge in the Metastatic Prostate Cancer Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metastatic Prostate Cancer Treatment Drugs
Metastatic Prostate Cancer Epidemiology Segmentation in the 7MM
Total Prevalent Cases of Prostate Cancer in the US
Total Diagnosed Prevalent Cases of Prostate Cancer in the US
Age-specific Cases of Prostate cancer in the US
Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the US
Total Metastatic Cases of Prostate Cancer (mCSPC and mCRPC) in the US
Total Treated Cases of mCRPC in the US
Metastatic Prostate Cancer Treatment Market
The Metastatic Prostate Cancer treatment market landscape encompasses a diverse array of therapeutic options, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, ionizing radiation emitters, and others across various lines of treatment. The recent emergence of PARP inhibitors, particularly for patients harboring mutations in DNA damage repair genes, has expanded personalized treatment approaches and offered hope for improved outcomes.
Discover key developments and opportunities in the Metastatic Prostate Cancer Market. Click here to learn more from DelveInsight’s latest report @ Metastatic Prostate Cancer Market Size
Metastatic Prostate Cancer Marketed Drugs
NUBEQA (darolutamide): Bayer
NUBEQA (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, inhibiting the receptor function and the growth of prostate cancer cells.
NUBEQA is indicated for treating adult patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel.
ERLEADA (apalutamide): Janssen
ERLEADA is a next-generation oral androgen receptor inhibitor that blocks the androgen-signaling pathway in prostate cancer cells. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the androgen receptor, by stopping the androgen receptor from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell. It is indicated for treating patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.
Emerging Metastatic Prostate Cancer Drugs
MGC018 (vobramitamab duocarmazine): MacroGenics
MGC018 (vobramitamab duocarmazine) is an investigational ADC comprised of a humanized B7-H3 mAb conjugated via a cleavable linker to the prodrug Seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA). MacroGenics began enrolling the TAMARACK Phase II study of vobramitamab duocarmazine (vobra duo) in patients with mCRPC under an amended protocol during the second quarter. This study is designed to evaluate vobra duo at two different doses, 2.0 mg/kg or 2.7 mg/kg every 4 weeks, across 100 patients. MacroGenics is also evaluating the activity of MGC018 plus lorigerlimab (an investigational PD-1 × CTLA-4 bispecific DART® molecule) in a Phase 1 study in patients with advanced solid tumors.
Bavdegalutamide (ARV-110): Arvinas
ARV-110 is an oral PROTAC protein degrader that targets the androgen receptor for potentially treating men with mCRPC and who have progressed on existing therapies. ARV-110 has demonstrated activity in preclinical models of androgen receptor mutation or overexpression, both common mechanisms of resistance to currently available androgen receptor-targeted therapies.
Metastatic Prostate Cancer Market Outlook
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a stage of prostate cancer that has spread to other parts of the body, such as lymph nodes or bones, and no longer responds to treatment that lowers testosterone. Despite currently approved therapeutics, mCRPC remains a terminal diagnosis with an aggressive disease course. ADT is a stalwart therapy for the initial treatment of metastatic disease. Unfortunately, most men in this situation will go on to develop mCRPC and require secondary systemic therapy. This disease state can be very challenging to treat.
Download DelveInsight’s Metastatic Prostate Cancer Market report today and stay ahead in this rapidly evolving field. @ Metastatic Prostate Cancer Clinical Trials
Scope of the Metastatic Prostate Cancer Market Report
Coverage- 7MM
Metastatic Prostate Cancer Companies- AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
Metastatic Prostate Cancer Therapies- ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.
Metastatic Prostate Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement
Download the report to understand which factors are driving Metastatic Prostate Cancer Market Trends @ Metastatic Prostate Cancer Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of Prostate Cancer
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Prostate Cancer Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management of Prostate Cancer
9 Treatment Guidelines
10 Epidemiology and Patient Population
11 Patient Journey
12 Marketed Therapies
13 Emerging Therapies
14 Prostate Cancer: Seven Major Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
